Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.
Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback